BR9916041A - Compound, pharmaceutical composition, and methods to inhibit the replication of a herpes virus and to treat a patient suffering from an infection with herpes virus - Google Patents
Compound, pharmaceutical composition, and methods to inhibit the replication of a herpes virus and to treat a patient suffering from an infection with herpes virusInfo
- Publication number
- BR9916041A BR9916041A BR9916041-2A BR9916041A BR9916041A BR 9916041 A BR9916041 A BR 9916041A BR 9916041 A BR9916041 A BR 9916041A BR 9916041 A BR9916041 A BR 9916041A
- Authority
- BR
- Brazil
- Prior art keywords
- carbon atoms
- alkyl
- herpes virus
- virus
- carbon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C335/20—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C335/22—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODOSPARA INIBIR A REPLICAçãO DE UM VìRUS DO HERPES EPARA TRATAR UM PACIENTE SOFRENDO DE UMA INFECçãOPOR VìRUS DO HERPES". Em que R~ 1~-R~ 5~ sãoindependentemente selecionados dentre hidrogênio, alquila de 1 a6 átomos de carbono, alquenila de 2 a 6 átomos de carbono,alquinila de 2 a 6 átomos de carbono, per-haloalquila de 1 a 6átomos de carbono, cicloalquila de 3 a 10 átomos de carbono,heterocicloalquila de 3 a 10 membros de carbono, arila, heteroarila,halogênio, -CN, -NO~ 2~, -CO~ 2~R~ 6~, COR~ 6~, -OR~ 6~,-SR~ 6~, -SOR~ 6~, -SO~ 2~R~ 6~, -CONR~ 7~R~ 8~, -NR~6~N (R~ 7~R~ 8~), -N(R~ 7~R~ 8~) ou W-Y-(CH~ 2~)~ n~-Z,com a condição de que pelo menos um de R~ 1~-R~ 5~ não éhidrogênio; ou R~ 2~ e R~ 3~ ou R~ 3~ e R~ 4~, tomados juntos,formam uma heterocicloalquila de 3 a 7 membros ou heteroarila de3 a 7 membros; R~ 6~ e R~ 7~ são independentementehidrogênio, alquila de 1 a 6 átomos de carbono, perhaloalquila de 1a 6 átomos de carbono, ou arila; R~ 8~ é hidrogênio, alquila de 1 a6 átomos de carbono, per-haloalquila de 1 a 6 átomos de carbono,cicloalquila de 3 a 10 átomos de carbono, heterocicloalquila de 3 a10 membros, arila ou heteroarila, ou R~ 7~ e R~ 8~, tomadosjuntos, podem formar uma heterocicloalquila de 3 a 7 membros; R~9~-R~ 12~ são independentemente hidrogênio, alquila de 1 a 4átomos de carbono, per-haloalquila de 1 a 4 átomos de carbono,halogênio, alcoxi de 1 a 4 átomos de carbono, ou ciano, ou R~ 9~e R~ 10~ ou R~ 11~, e R~ 12~ podem ser tomados juntos paraformar arila de 5 a 7 átomos de carbono; W é 0, NR~ 6~ ou estáausente; Y é -(CO)-ou -(CO~ 2~)-, ou está ausente; Z é alquila de 1a 4 átomos de carbono, -CN, -CO~ 2~R~ 6~, -COR~ 6~, CONR~7~R~ 8~, -OCOR~ 6~, -NR~ 6~COR~ 7~, -OCONR~ 6~, -OR~6~, -SOR~ 6~, -SO~ 2~ R~ 6~, SR~ 6~N(R~ 7~R~ 8~), -N (R~7~R~ 8~) ou fenila; G é alquila de 1 a 6 átomos de carbono, X éuma ligação, -NH, alquila de 1 a 6 átomos de carbono, alquenila de1 a 6 átomos de carbono, alcoxi de 1 a 6 átomos de carbono,tioalquila de 1 a 6 átomos de carbono, alquilamino de 1 a 6 átomosde carbono, ou (CH)J; J é alquila de 1 a 6 átomos de carbono,cicloalquila de 3 a 7 átomos de carbono, fenila ou benzila; e n é uminteiro de 1 a 6; ou sais 1 farmacêuticos dos mesmos, sãoutilizáveis no tratamento de doenças associadas com vírus doherpes incluindo citomegalovírus humano, vírus de herpes simplex,vírus Epstein-Barr, vírus de varicella-zoster, vírus de herpeshumano 6 e 7, e vírus de herpes de Kaposi."COMPOUND, PHARMACEUTICAL COMPOSITION, AND, METHODS TO INHIBIT THE REPLICATION OF A HERPES VIRUS AND TO TREAT A PATIENT SUFFECTING AN INFECTION BY HERPES VIRUS". Where R ~ 1 ~ -R ~ 5 ~ are independently selected from hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, perhaloalkyl of 1 to 6 atoms of carbon, cycloalkyl of 3 to 10 carbon atoms, heterocycloalkyl of 3 to 10 carbon members, aryl, heteroaryl, halogen, -CN, -NO ~ 2 ~, -CO ~ 2 ~ R ~ 6 ~, COR ~ 6 ~, -OR ~ 6 ~, -SR ~ 6 ~, -SOR ~ 6 ~, -SO ~ 2 ~ R ~ 6 ~, -CONR ~ 7 ~ R ~ 8 ~, -NR ~ 6 ~ N (R ~ 7 ~ R ~ 8 ~), -N (R ~ 7 ~ R ~ 8 ~) or WY- (CH ~ 2 ~) ~ n ~ -Z, with the proviso that at least one of R ~ 1 ~ -R ~ 5 ~ it is not hydrogen; or R ~ 2 ~ and R ~ 3 ~ or R ~ 3 ~ and R ~ 4 ~, taken together, form a 3- to 7-membered heterocycloalkyl or 3- to 7-membered heteroaryl; R ~ 6 ~ and R ~ 7 ~ are independently hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, or aryl; R ~ 8 ~ is hydrogen, alkyl of 1 to 6 carbon atoms, perhaloalkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, 3 to 10 membered heterocycloalkyl, aryl or heteroaryl, or R ~ 7 ~ and R ~ 8 ~, taken together, can form a 3- to 7-membered heterocycloalkyl; R ~ 9 ~ -R ~ 12 ~ are independently hydrogen, alkyl of 1 to 4 carbon atoms, perhaloalkyl of 1 to 4 carbon atoms, halogen, alkoxy of 1 to 4 carbon atoms, or cyan, or R ~ 9 ~ and R ~ 10 ~ or R ~ 11 ~, and R ~ 12 ~ can be taken together to form aryl of 5 to 7 carbon atoms; W is 0, NR ~ 6 ~ or absent; Y is - (CO) -or - (CO ~ 2 ~) -, or is absent; Z is alkyl of 1 to 4 carbon atoms, -CN, -CO ~ 2 ~ R ~ 6 ~, -COR ~ 6 ~, CONR ~ 7 ~ R ~ 8 ~, -COLOR ~ 6 ~, -NR ~ 6 ~ COLOR ~ 7 ~, -OCONR ~ 6 ~, -OR ~ 6 ~, -SOR ~ 6 ~, -SO ~ 2 ~ R ~ 6 ~, SR ~ 6 ~ N (R ~ 7 ~ R ~ 8 ~), -N (R ~ 7 ~ R ~ 8 ~) or phenyl; G is alkyl of 1 to 6 carbon atoms, X is a bond, -NH, alkyl of 1 to 6 carbon atoms, alkenyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, thioalkyl of 1 to 6 atoms carbon, alkylamino of 1 to 6 carbon atoms, or (CH) J; J is alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, phenyl or benzyl; and n is 1 to 6; or pharmaceutical salts thereof, are usable in the treatment of diseases associated with doherpes viruses including human cytomegalovirus, herpes simplex virus, Epstein-Barr virus, varicella-zoster virus, herpeshuman virus 6 and 7, and Kaposi herpes virus.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20831698A | 1998-12-09 | 1998-12-09 | |
| PCT/US1999/028844 WO2000034237A2 (en) | 1998-12-09 | 1999-12-06 | Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9916041A true BR9916041A (en) | 2001-12-04 |
Family
ID=22774137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9916041-2A BR9916041A (en) | 1998-12-09 | 1999-12-06 | Compound, pharmaceutical composition, and methods to inhibit the replication of a herpes virus and to treat a patient suffering from an infection with herpes virus |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1137633A2 (en) |
| JP (1) | JP2002531544A (en) |
| KR (1) | KR20010087413A (en) |
| CN (1) | CN1333750A (en) |
| AU (1) | AU3111200A (en) |
| BR (1) | BR9916041A (en) |
| CA (1) | CA2350899A1 (en) |
| CZ (1) | CZ20012060A3 (en) |
| EA (1) | EA200100640A1 (en) |
| HU (1) | HUP0104944A3 (en) |
| IL (1) | IL143204A0 (en) |
| NO (1) | NO20012834L (en) |
| PL (1) | PL349131A1 (en) |
| WO (1) | WO2000034237A2 (en) |
| ZA (1) | ZA200104142B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6166028A (en) * | 1998-12-09 | 2000-12-26 | American Home Products Corporation | Diaminopuridine-containing thiourea inhibitors of herpes viruses |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| JP4690889B2 (en) * | 2002-10-24 | 2011-06-01 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Methylene urea derivative |
| US7220768B2 (en) * | 2003-02-11 | 2007-05-22 | Wyeth Holdings Corp. | Isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus |
| EP1660661A2 (en) | 2003-08-08 | 2006-05-31 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
| CA2772017C (en) | 2003-08-29 | 2016-05-31 | Mitsui Chemicals, Inc. | Agricultural/horticultural insecticide and method for using the same |
| AU2005221151A1 (en) | 2004-03-09 | 2005-09-22 | Arriva Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
| EP2074085A2 (en) * | 2006-10-13 | 2009-07-01 | Lica Pharmaceuticals A/S | Anti-infective thiourea compounds |
| ES2382055T3 (en) | 2006-11-02 | 2012-06-04 | Millennium Pharmaceuticals, Inc. | Methods for synthesizing pharmaceutical salts of a factor Xa inhibitor |
| CN108619123A (en) * | 2018-03-13 | 2018-10-09 | 武汉威立得生物医药有限公司 | Tenovin-1 is preparing the application in preventing nerpes vinrus hominis's infection medicine |
| WO2019193541A1 (en) * | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| CN112807294B (en) * | 2019-11-18 | 2023-09-05 | 武汉大学 | Application of acyl thiourea compound in preparation of medicines for treating or preventing herpes simplex virus type I infection |
| WO2022150962A1 (en) * | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Protease inhibitors, preparation, and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69830751T2 (en) * | 1997-04-10 | 2006-05-18 | Pharmacia & Upjohn Co. Llc, Kalamazoo | Polyaromatic compounds for the treatment of herpes infections |
-
1999
- 1999-12-06 JP JP2000586685A patent/JP2002531544A/en active Pending
- 1999-12-06 EA EA200100640A patent/EA200100640A1/en unknown
- 1999-12-06 PL PL99349131A patent/PL349131A1/en not_active Application Discontinuation
- 1999-12-06 HU HU0104944A patent/HUP0104944A3/en unknown
- 1999-12-06 WO PCT/US1999/028844 patent/WO2000034237A2/en not_active Application Discontinuation
- 1999-12-06 EP EP99965132A patent/EP1137633A2/en not_active Withdrawn
- 1999-12-06 IL IL14320499A patent/IL143204A0/en unknown
- 1999-12-06 BR BR9916041-2A patent/BR9916041A/en not_active Application Discontinuation
- 1999-12-06 CA CA002350899A patent/CA2350899A1/en not_active Abandoned
- 1999-12-06 KR KR1020017007052A patent/KR20010087413A/en not_active Application Discontinuation
- 1999-12-06 CN CN99815640A patent/CN1333750A/en active Pending
- 1999-12-06 CZ CZ20012060A patent/CZ20012060A3/en unknown
- 1999-12-06 AU AU31112/00A patent/AU3111200A/en not_active Abandoned
-
2001
- 2001-05-21 ZA ZA200104142A patent/ZA200104142B/en unknown
- 2001-06-08 NO NO20012834A patent/NO20012834L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20012834L (en) | 2001-08-07 |
| CZ20012060A3 (en) | 2001-11-14 |
| CN1333750A (en) | 2002-01-30 |
| HUP0104944A2 (en) | 2002-04-29 |
| EA200100640A1 (en) | 2001-12-24 |
| CA2350899A1 (en) | 2000-06-15 |
| WO2000034237A2 (en) | 2000-06-15 |
| KR20010087413A (en) | 2001-09-15 |
| AU3111200A (en) | 2000-06-26 |
| ZA200104142B (en) | 2002-10-25 |
| EP1137633A2 (en) | 2001-10-04 |
| NO20012834D0 (en) | 2001-06-08 |
| HUP0104944A3 (en) | 2003-03-28 |
| JP2002531544A (en) | 2002-09-24 |
| WO2000034237A3 (en) | 2000-11-23 |
| IL143204A0 (en) | 2002-04-21 |
| PL349131A1 (en) | 2002-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9916041A (en) | Compound, pharmaceutical composition, and methods to inhibit the replication of a herpes virus and to treat a patient suffering from an infection with herpes virus | |
| EA200000990A1 (en) | HIV INHIBITIVE PYRIMIDINE DERIVATIVES | |
| DK0513104T3 (en) | Use of an alpha-tocopherol phosphate or one of its derivatives for the manufacture of cosmetic, dermatological or pharmaceutical preparations, and thus obtained preparations | |
| EA200000993A1 (en) | TRIPLE-SUBSTITUTE DERIVATIVES 1,3,5-TRIAZINE FOR THE TREATMENT OF HIV INFECTIOUS DISEASES | |
| AU644095B2 (en) | Antiviral compounds | |
| CA2197319A1 (en) | Lipid analogs for treating viral infections | |
| NZ505362A (en) | 4-hydroxyquinoline-3-carboxamides and -hydrazides useful as antiviral agents | |
| BR9916086A (en) | Compound, pharmaceutical composition, method for inhibiting the replication of a herpes virus, method for treating a patient suffering from a herpes virus infection | |
| DK1224940T3 (en) | Liquid formulations of interferon-beta | |
| BR9916084A (en) | Compound, pharmaceutical composition, and, processes to inhibit the replication of a herpes virus, and to treat a patient suffering from a herpes virus infection | |
| BR9916046A (en) | Compound, pharmaceutical composition, and processes for inhibiting the replication of a herpes virus and for treating a patient suffering from a herpes virus infection | |
| DK0534445T3 (en) | Process for the preparation of a medicament for oral or topical administration in the treatment of Leishmaniasis | |
| BR9916042A (en) | Compound, pharmaceutical composition, and processes to inhibit the replication of a herpes virus, and treatment of a patient suffering from a herpes virus infection | |
| ATE173252T1 (en) | ARYL MORPHOLINES, PREPARATION AND USE | |
| NO983090L (en) | Therapeutic compounds | |
| EA200100639A1 (en) | TIOMOCHEVIN DERIVATIVES CONTAINING HETEROCYCLIC CARBOXAMIDE AND PROTECTIVE PHENYLETHYLENAMINE GROUP, AS HERPES VIRUS INHIBITORS | |
| ATE59778T1 (en) | USE OF SULFONAMIDE DERIVATIVES IN THE MANUFACTURE OF AN ANTIVIRUS AGENT. | |
| BR9915993A (en) | Compound, pharmaceutical composition, process to inhibit the replication of a herpes virus, and process to treat a patient suffering from a herpes virus infection | |
| PT1120415E (en) | REPLACED ISOXAZOLYLTHOPHENE COMPOUNDS | |
| FI906268A0 (en) | 2-FORMYLBENZYLFOSFONSYRADERIVAT, DERAS FRAMSTAELLNING OCH DERAS ANVAENDNING VID VAORD AV SJUKDOMAR FOERORSAKADE AV VIRUS. | |
| DK0586298T3 (en) | Inhibitor of viral herpes simplex thymidine kinase | |
| ATE320260T1 (en) | SULFUR CONTAINING PHOSPHONOFORMATE DERIVATIVES AND THEIR USE. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |